Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

908 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Lee J, et al. Among authors: park kw, park ys, park jo, park sh, park k. Cancer Chemother Pharmacol. 2004 Nov;54(5):385-90. doi: 10.1007/s00280-004-0837-7. Epub 2004 Jul 10. Cancer Chemother Pharmacol. 2004. PMID: 15248028 Clinical Trial.
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
Park SH, Kang WK, Lee HR, Park J, Lee KE, Lee SH, Park JO, Kim K, Kim WS, Chung CW, Im YH, Lee MH, Park CH, Park K. Park SH, et al. Among authors: park jo, park ch, park k, park j. Am J Clin Oncol. 2004 Oct;27(5):477-80. doi: 10.1097/01.coc.0000136018.81814.79. Am J Clin Oncol. 2004. PMID: 15596914 Clinical Trial.
Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy.
Lee J, Park YH, Kim WS, Lee SS, Ryoo BY, Yang SH, Park KW, Kang JH, Park JO, Lee SH, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Ko YH, Ahn YC, Park K. Lee J, et al. Among authors: park yh, park kw, park ys, park jo, park k. Eur J Cancer. 2005 Jul;41(10):1402-8. doi: 10.1016/j.ejca.2005.03.010. Eur J Cancer. 2005. PMID: 15963893
A phase II study of oxaliplatin in combination with doxorubicin as first-line systemic chemotherapy in patients with inoperable hepatocellular carcinoma.
Uhm JE, Park JO, Lee J, Park YS, Park SH, Yoo BC, Paik SW, Koh KC, Kang WK, Lim HY. Uhm JE, et al. Among authors: park ys, park jo, park sh. Cancer Chemother Pharmacol. 2009 Apr;63(5):929-35. doi: 10.1007/s00280-008-0817-4. Epub 2008 Aug 23. Cancer Chemother Pharmacol. 2009. PMID: 18726098 Clinical Trial.
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.
Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK. Yi SY, et al. Among authors: park mj, park ys, park sh, park jo. Cancer Chemother Pharmacol. 2009 May;63(6):1141-5. doi: 10.1007/s00280-008-0839-y. Epub 2008 Oct 7. Cancer Chemother Pharmacol. 2009. PMID: 18839175 Clinical Trial.
A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.
Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK. Ryu MH, et al. Among authors: park ys, park jo. Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. Oncology. 2009. PMID: 19307738 Clinical Trial.
908 results